Merck secured FDA approval for a subcutaneous formulation of Keytruda, the company's leading cancer immunotherapy drug. This new delivery method is designed to improve patient convenience while helping Merck maintain market dominance amid increasing biosimilar competition. The approval is expected to bolster Keytruda's usage across multiple cancer indications worldwide.